The FDA released draft guidance outlining the nonclinical testing, clinical evidence, and labeling it expects in premarket submissions for robotically assisted surgical devices. The guidance applies to software-controlled systems that help practitioners position and control instruments during open, minimally invasive, or endoluminal procedures. Comments are due Nov. 24.  

The FDA also scheduled a Dec. 2–3 workshop focused on autonomous and remotely operated robotic devices. The agency plans to examine terminology, technical considerations, and the benefits and risks associated with greater device autonomy and remote control.  

This is an important regulatory signal for surgical-services leaders and hospitals evaluating robotic platforms. More consistent evidence requirements could shape product development, market entry, and the information available to value analysis teams comparing systems. The guidance also creates a timely opening to examine:

·       Clinical evidence behind new platforms and indications.

·       Human-factors testing and emergency conversion procedures.

·       Instrument compatibility and validated reprocessing instructions.

·       Software, interoperability, and cybersecurity requirements.

·       Training, credentialing, and learning curve expectations.

·       Capital, service, disposable instrument, and infrastructure costs.

The separate workshop shows the FDA is already looking beyond conventional surgeon-controlled systems toward remote and increasingly autonomous capabilities—technologies that will raise additional questions about connectivity, latency, cybersecurity, staffing, and accountability.